Mikel Portu

Real-world analysis of MET exon 14 mutations in non-small cell lung cancer: a retrospective study from two Swedish hospitals. tandfonline.com/doi/full/10.10…

Happy to share our comprehensive review on MiT-RCC — now published in @Cancers_MDPI! 🔗 doi.org/10.3390/cancer… TFE3/TFEB-driven kidney cancers are rare but increasingly treatable. We review the molecular biology, modern diagnostics, and emerging evidence for ICI + VEGFR-TKI combinations in metastatic tRCC. Key takeaway: fusion partner identity shapes both prognosis and treatment response. Precision matters. Thanks to the whole team — @MarioBalsaMD @OncoSantPau @ICO_oncologia @myESMO @_SEOM @OncoAlert @Uromigos @IKCCorg @RenalCancerNews

Our new review is out! 📚 @Cancers_MDPI 🔗 mdpi.com/2072-6694/18/6… 🤔 TFE3-rearranged and TFEB-altered renal cell carcinomas remain among the most fascinating (and challenging) entities within MiT family RCCs In this review we dissect: 🧬 Molecular landscape of MiT-RCC 🎯 Key diagnostic tools (GPNMB IHC, TRIM63 RNA ISH…) 💥 Emerging evidence for ICI + VEGFR-TKI combinations in M1 disease In MiT-RCC, when TFE3/TFEB rearrange the genome…they also rearrange the way we think about kidney cancer 💡 Thank you to my friend @MGrive92 and to all the team from @OncoSantPau & @ICO_oncologia! @OncoAlert @OncoReporte @myESMO @_SEOM @Uromigos @IKCCorg @RenalCancerNews

@MarioBalsaMD @Cancers_MDPI @OncoSantPau

Letetresgene autoleucel in advanced non-small cell lung cancer: a step towards truly personalized immunotherapy? tlcr.amegroups.org/article/view/1…

🏆 #EMUC25 Best Abstract Award - M.I. Galante Romo, Madrid (ES) For the paper: "Real world evidence of adjuvant pembrolizumab in renal cell carcinoma (RCC) from a Spanish registry: The ARENAL trial from the GUARD consortium."

Soon finishing day 2 of our 14th ETOP Residential Workshop with great presentations from the faculty, very interesting project proposals from our participants and lively discussions.

First-Line Osimertinib in a Patient Having NSCLC With a Rare Duplication Mutation in the EGFR Exon 19 Region (NM_005228.5:c.2214_2231dup p.(Ile740_Lys745dup)) - Clinical Lung Cancer clinical-lung-cancer.com/article/S1525-…

Molecular Determinants of Survival in Metastatic Uveal Melanoma: The I... sciencedirect.com/science/articl…

Magnífica presentació de “First line (1L) fulzerasib + cetuximab in KRAS G12Cm advanced NSCLC: Updated efficacy and safety from KROCUS study” per @margamajem @OncoSantPau @myESMO #ELCC25

@twobitidiot Why do you lie so blatantly?

The XRP and ADA “communities” are the loudest and least valuable bot groups on X. Ship something, and then I’ll respond. I have no animosity towards people that make money. But where are the users. You can’t gaslight me, idiots, I’ve been around too long and dgaf about mobs.

💜 Cursa anual benèfica per la investigació en Càncer Renal ‼️#els10dlf 🏃‍♂️🏃🏃‍♀️ 10km 📅 Diumenge 17 de Novembre 🕙 10h Inscripcions: xipgroc.cat/ca/curses/LesF… @HospitalSantPau @IRSantPau @Maroto5Pablo @GeorgiaAnpa @MGrive92

THEOREMM: A Novel Framework for Cancer Registration Trials. "Trials in HEmatology and Oncology REviewed by Metaresearch Methods" drugdevletter.com/p/theoremm-a-n… via @VPrasadMDMPH & @Timothee_MD

Avui hem fet l'acte de comiat dels i les residents de darrer any de l'@ICO_oncologia. Enhorabona per haver finalitzat l'especialitat i molts èxits en aquesta nova etapa que ara comenceu! De ben segur esteu preparats! 💪 #ICONICpeople #residents

Great time at #GUARDSymposium2024

Bladder surgery sparing approaches will superceed cystectomy according to @AndreaNecchi . #GUARDSymposium2024

@ParronSierra Poco a poco!

Soy demasiado ineficiente haciendo informes

@Steven_Hyden So good. In the car outside should have been a huge hit

Fascinating album.

@FluidTokens When Yoroi integration?

Boosted Stake TVL is over 2,000,000 $ADA 🔥 And we just released a UI update ✨